BELLEVILLE, ON, Nov. 4, 2013 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has hired Dr.
Michael Berendt as its new CEO effective immediately. Dr. Berendt
replaces Mr. Graeme McRae in this role. Earlier this year, Mr. McRae
announced his intention to retire and assume the role of Founder and
Chairman Emeritus of the Company's Board of Directors.
"The Board of Directors, management team, employees and shareholders
acknowledge Graeme's significant contribution, while welcoming Dr.
Berendt to the Bioniche team," said Mr. James Rae, Chairman of the
Bioniche Life Sciences Inc. Board of Directors. "Dr. Berendt has an
established background in the life sciences sector, most recently
serving as President & CEO of Aegera Therapeutics Inc. in Montréal,
Dr. Berendt held positions of increasing responsibility in the U.S.
research departments of Pfizer, Inc. and Bayer Corporation before
becoming Managing Director, Life Sciences Sector of AEA Investors, then
Managing Director of Research Corporation Technologies. In 2006, he
became the President & CEO of Aegera, which was sold to Pharmascience
Dr. Berendt graduated with a B.S. from Ohio Dominican University, a M.S.
from Miami University, and a Ph.D. in Medical Microbiology and
Immunology from Drexel University. Dr. Berendt is a Director on the
Boards of Waters Corporation and NeoMed Institute. He serves as
Executive Chairman of Anchor Therapeutics and serves as Chairman of
Dr. Berendt will be attending the Company's Annual and Special Meeting
of Shareholders, being held on Tuesday, November 5, 2013 at 4:00 p.m.
Eastern in Belleville, Ontario.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and One
Health. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097